Scarica l'app Stockscreener
755.90
2.56%
18.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$737.00
Aprire:
$736.01
Volume 24 ore:
1.43M
Relative Volume:
1.32
Capitalizzazione di mercato:
$78.07B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
18.10
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
+9.00%
1M Prestazione:
+30.48%
6M Prestazione:
+25.02%
1 anno Prestazione:
+1.53%
Intervallo 1D:
$735.74
$764.09
Intervallo di 1 settimana:
$692.29
$764.09
Portata 52W:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by DNB Asset Management AS - MarketBeat
A Fresh Look at Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Expands Eylea HD’s Market Potential - simplywall.st
Jim Cramer Answered Questions About These 7 Stocks - Insider Monkey
Franklin Resources Inc. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Entropy Technologies LP - MarketBeat
ABN AMRO Bank N.V. Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading 4.6% Higher on Analyst Upgrade - MarketBeat
UC Berkeley dean’s research inspires emerging treatment for rare bone disease - University of California, Berkeley
Wells Fargo & Company Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $700.00 - MarketBeat
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO - Ophthalmology Times
Wealthspire Advisors LLC Sells 3,213 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock? - Barchart.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Vanguard Group Inc. - MarketBeat
Sinusitis Drugs Market Generated Opportunities, Future Scope - openPR.com
Creative Planning Has $4.98 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shifts2025 Institutional Moves & Growth Focused Entry Point Reports - newser.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Regeneron Stock: Latest Approvals and Market Shifts - StocksToTrade
Expanded FDA Approvals and Pipeline Wins Could Be a Game Changer For Regeneron Pharmaceuticals (REGN) - simplywall.st
FDA Approves Aflibercept Injection for Macular Edema Following Retinal Vein Occlusion - Drug Topics
Dir Bassler Files To Sell 760 Of Regeneron Pharmaceuticals Inc [REGN] - TradingView
New Approvals Propel Regeneron Stock - timothysykes.com
Novartis, Moderna detail manufacturing expansions in the US, among others - Endpoints News
Regeneron wins 2 Eylea nods, ramping up competition with Roche - Fierce Pharma
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss - Benzinga
With new approvals, Regeneron’s higher-dose Eylea gets more competitive - BioPharma Dive
Wells Fargo Raises Price Target for REGN to $700 | REGN Stock News - GuruFocus
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD - Yahoo Finance
EC approval for Libtayo as adjuvant treatment of high-risk CSCC - The Pharma Letter
Seizert Capital Partners LLC Has $45.14 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Hands Regeneron Two Eylea HD Nods in One Day - BioSpace
Bernstein reiterates Outperform rating on Regeneron stock at $818 - Investing.com India
Regeneron’s Eylea franchise boosted by pair of FDA approvals - Yahoo Finance
United States AMD Drug Market 2025: Get Exclusive Data | Top 5 - openPR.com
Intrust Bank NA Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Raymond James Adjusts PT on Regeneron Pharmaceuticals to $800 From $723, Keeps Outperform Rating - MarketScreener
Nomura Asset Management Co. Ltd. Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is favored by hedge fundsProfit Target & Weekly Momentum Stock Picks - newser.com
Rockefeller Capital Management L.P. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meridian Wealth Management LLC Lowers Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stocks to Watch Thursday: Walmart, Nvidia, Cracker Barrel, Regeneron - The Wall Street Journal
Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold - MSN
How strong is Regeneron Pharmaceuticals Inc. stock balance sheetTreasury Yields & Daily Market Momentum Tracking - newser.com
Why analysts raise outlook for Regeneron Pharmaceuticals Inc. (RGO) stockQuarterly Profit Review & Capital Efficiency Focused Strategies - newser.com
Stocks to Watch : Nvidia, Kulicke & Soffa, Regeneron - MarketScreener
Regeneron (REGN) Gains FDA Approval for Eylea HD Injection - GuruFocus
Regeneron Pharmaceuticals, Inc.: - MarketScreener
Regeneron Announces Plans To Establish New Drug Manufacturing Facility In Saratoga Springs NY - Pharmaceutical Online
Regeneron Gets FDA Approval for Eylea to Treat Macular Edema - MarketScreener
Regeneron gets FDA nod for Eylea in macular edema treatment - Seeking Alpha
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.11%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):